CGIX - キャンサ―・ジェネティクス （Cancer Genetics Inc.） キャンサ―・ジェネティクスCGIXのチャート
CGIXの企業情報
| symbol | CGIx |
|---|---|
| 会社名 | Cancer Genetics Inc. （キャンサ―・ジェネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | ヘルスケア施設_サ―ビス 医療関連（Health Care） |
| 概要 | 事業概要 キャンサー・ジェネティクス(Cancer Genetics Inc)は米国ベースの診断会社である。同社は癌の診断、予後と治療への応答を改善するためにゲノムテストと関連サービスの開発・商業化を中心に行っている。これらの癌は血液、尿生殖器及びヒトパピローマウイルス（HPV）に関連する癌を含む。同社は病院、がんセンター、医師のオフィスで腫瘍医や病理医にそのテストとサービスを提供する。同社はマイクロアレイとプローブの２種類のデオキシリボ核酸(DNA)ベースのゲノムテストを開発・生産している。同社は慢性リンパ性白血病（CLL）のためのマイクロアレイ試験である｢MatBA-CLL｣を提供し、その腫瘍学市場で他のゲノムテストを開発している。同社はイタリアのミラノに事務所を有している。 キャンサ―・ジェネティクスは、米国のがん診断製品開発会社。がん治療のための診断、予後診断、また個人に特化するゲノム検査やサ―ビスの開発、商品化を手掛ける。がん専門医や病理学者、がんセンタ―、診療所のほか、バイオ製薬企業や臨床研究機関を対象に、一般の腫瘍学向け検査や研究サ―ビスとともにゲノム検査およびサ―ビスを提供する。 |
| 本社所在地 | 201 Route 17 North 2nd Floor Rutherford NJ 07070 USA |
| 代表者氏名 | John A. Roberts ジョンA.ロバーツ |
| 代表者役職名 | President Chief Executive Officer |
| 電話番号 | +1 201-528-9200 |
| 設立年月日 | 36251 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 245人 |
| url | www.cancergenetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cgix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -20.73900 |
| 終値（lastsale） | 0.9099 |
| 時価総額（marketcap） | 25246537.6203 |
| 時価総額 | 時価総額（百万ドル） 22.89086 |
| 売上高 | 売上高（百万ドル） 30.25400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 31.61386 |
| 当期純利益 | 当期純利益（百万ドル） -1.41800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cancer Genetics Inc revenues increased 8% to $14.7M. Net loss decreased 34% to $8.1M. Revenues reflect Revenue Discovery Services increase from $556K to $3M Revenue Biopharma Services increase of 3% to $7.2M. Lower net loss reflects Change in fair value of warrant liabilit increase from $6.7M (expense) to $2.8M (income) Research and Development - decrease of 34% to $1.3M (expense). |
CGIXのテクニカル分析
CGIXのニュース
Cancer Genetics Inc. Shares Close the Week 69.7% Higher - Weekly Wrap 2021/02/12 22:30:00 Kwhen Finance
Cancer Genetics Inc. shares closed this week 69.7% higher than it did at the end of last week. The stock is currently up 142.6% year-to-date, up 36.6% over the past 12 months, and down 90.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.3%. Trading Activity Shares traded as high as $17.50 and as low as $4.01 this week.Shares closed 6e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 10.0% higher than the 10-day average and 143.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 802.8% The company's stock price performance over the past 12 months beats the peer average by 137.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Cancer Genetics Inc. Shares Close the Week 69.7% Higher - Weekly Wrap 2021/02/12 22:30:00 Kwhen Finance
Cancer Genetics Inc. shares closed this week 69.7% higher than it did at the end of last week. The stock is currently up 142.6% year-to-date, up 36.6% over the past 12 months, and down 90.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.3%. Trading Activity Shares traded as high as $17.50 and as low as $4.01 this week.Shares closed 6e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 10.0% higher than the 10-day average and 143.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 802.8% The company's stock price performance over the past 12 months beats the peer average by 137.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.